FDA Approves Treprostinil Inhalation Powder to Expand Treatment for PAH and PH-ILD Dr. Kamal Kant Kohli26 May 2025 11:00 PM ISTThe US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog designed to enhance exercise...
Natco Pharma gets final approval for Bosentan tablets for oral suspension Ruchika Sharma10 Feb 2025 11:30 AM ISTHyderabad: NATCO Pharma Limited has announced final approval of its Abbreviated New Drug Application (ANDA) for Bosentan tablets for oral...
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension Ruchika Sharma31 Jan 2025 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating WINREVAIR...
Novel PET approach may identify early signs of pulmonary arterial hypertension, highlights research Dr. Kamal Kant Kohli24 Jan 2025 7:30 AM ISTA new molecular imaging technique-18F-FAPI PET-can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH),...
Merck gets UK approval for lung disease drug Sotatercept Ruchika Sharma1 Jan 2025 3:13 PM ISTMerck has received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, to treat a rare lung...
ZENITH Trial Breakthrough: Winrevair Shows Significant Impact on Outcomes of Pulmonary Arterial Hypertension Medha Baranwal4 Dec 2024 8:00 PM ISTUSA: In patients with advanced pulmonary arterial hypertension (PAH), adding the biologic sotatercept-csrk (Winrevair; Merck) to the maximum tolerated...
Asporin Promising Protective Target in Pulmonary Arterial Hypertension Identifies New Multiomics Study Medha Baranwal18 Nov 2024 9:00 PM ISTUSA: A recent study published in the journal Circulation has revealed that the asporin gene could be a promising therapeutic target for patients with...
Rare Disease Show Episode 19: Decoding Pulmonary Arterial Hypertension with Dr Brajesh Kumar Mishra Dr. Nandita Mohan12 Nov 2024 9:15 PM ISTMedical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are medical conditions that...
Resistin Emerges as Key Predictor of Mortality and Disease Severity in Pulmonary Arterial Hypertension: Study Medha Baranwal31 July 2024 7:30 AM ISTUSA: Elevated levels of the cytokine resistin were strongly linked to a higher risk of mortality in adults with pulmonary arterial hypertension (PAH),...
Pulmonary arterial hypertension treatment: USFDA gives tentative nod to Alembic Pharma Selexipag for Injection Ruchika Sharma13 July 2024 1:30 PM ISTVadodara: Alembic Pharmaceuticals Limited has announced that the Company has received tentative approval from the US Food & Drug...
Seralutinib effective in managing pulmonary arterial hypertension: Lancet Jacinthlyn Sylvia15 May 2024 9:30 AM ISTIn the field of pulmonary arterial hypertension (PAH), where morbidity and mortality rates remain alarmingly high, a new inhaled drug can greatly...
USFDA approves Alembic Pharma five products in over a month Ruchika Sharma9 May 2024 1:05 PM ISTMumbai: Alembic Pharmaceuticals Limited announced today that it has received US Food & Drug Administration (USFDA) approvals on five of its...
